drugset
drugset / Trial / NCT00544882

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

NCT00544882 ↗

Phase 3 Completed 61 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multi-center study to evaluate hormone levels with the oral contraceptive regimen DR-1021.

Timeline

Start
2007-10-31
Primary completion
2008-03-31
Completion
2008-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject DR-1021 Unknown 10 ug Oral
Subject DR-1021 Unknown 20 ug Oral
Subject DR-1021 Unknown 150 ug Oral
Comparator Desogestrel Small molecule 10 ug Oral
Comparator Desogestrel Small molecule 20 ug Oral
Comparator Desogestrel Small molecule 150 ug Oral
Background Kariva Unknown 10 ug Oral
Background Kariva Unknown 20 ug Oral
Background Kariva Unknown 150 ug Oral

Indications

No indication recorded.